Table 3 Saturation effect analysis between FLI and new-onset hyperuricemia.

From: Decoding the fatty liver-hyperuricemia link in the obese and nonobese hypertensive patients: insights from a cohort study

Outcome

New-onset hyperuricemia

HR (95% CI), p value

New-onset hyperuricemia 10

HR (95% CI), p value

New-onset hyperuricemia 20

HR (95% CI), p value

Model I

A straight-line effect

1.11 (0.92, 1.35), 0.277

1.17 (0.89, 1.52), 0.262

1.36 (0.93, 1.99), 0.114

Model II

 Inflection point:

18.95

13.55

19.86

  ≤ Inflection point

2.19 (1.30, 3.67), 0.003

4.00 (1.37, 11.69), 0.011

3.44 (1.28, 9.22), 0.014

  > Inflection point

1.13 (0.92, 1.38), 0.235

1.25 (0.93, 1.66), 0.136

1.39 (0.93, 2.08), 0.106

 p for log likelihood ratio test

0.004

0.016

0.039

  1. Model I and II were adjusted for sex, age, systolic blood pressure, diastolic blood pressure, diabetes, chronic kidney disease, current smoking, homocysteine, fasting blood glucose, total cholesterol, alanine aminotransferase, albumin, LDL-C, eGFR, antihypertensive drugs, glucose-lowering drugs, lipid-lowering drugs, antiplatelet drugs, body mass index, triglyceride, glutamyl transpeptidase and waist-hip ratio.
  2. HR hazard ratio, 95% CI 95% confidence interval, FLI fatty liver index, LDL-C low-density lipoprotein cholesterol, eGFR estimate glomerular filtration rate.
Back to article page